65
Participants
Start Date
June 26, 2017
Primary Completion Date
August 12, 2022
Study Completion Date
August 12, 2023
Venetoclax
"Beginning with 400mg daily on days 1-10 of cycle 1-3~Phase I dose escalation scheme:~Dose Level -2 (DL-2): 100 mg daily, days 1-10, cycle 1-3~DL-1: 200 mg daily, days 1-10, cycle 1-3~DL1: 400 mg daily, days 1-10, cycle 1-3~DL2: 600 mg daily, days 1-10, cycle 1-3~DL3: 800 mg daily, days 1-10, cycle 1-3~Phase II: Given at a dose of 400mg daily for 5 days"
Rituximab
"Part of R-ICE treatment:~Rituximab: 375 mg/m\^2 intravenously (IV) on Day 1 of R-ICE every 21 days"
Ifosfamide
"Part of R-ICE treatment:~Ifosfamide: 5,000 mg/m\^2 mixed together with mesna at a dose of 5,000 mg/m\^2 over 24 hours beginning on Day 2 and completing on Day 3 of each 21-day cycle"
Carboplatin
"Part of R-ICE treatment:~Carboplatin: At a dose corresponding to an AUC = 5 based on Cockcroft-Gault calculation of GFR using adjusted body weight. Carboplatin is given IV on the Day 2 of RICE of each 21 day cycle"
Etoposide
"Part of R-ICE treatment:~Etoposide: 100 mg/m2by IV daily on 3 consecutive days (Days 1-3) of each 21-day cycle"
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
Washington University School of Medicine, Siteman Cancer Center, St Louis
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland
Molly Gallogly
OTHER